CSIMarket
 


Essa Pharma inc   (EPIX)
Other Ticker:  
 

Essa Pharma Inc 's Tangible Leverage Ratio

EPIX's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 11.47%, Tangible Leverage Ratio fell to 0.03, below the Essa Pharma Inc 's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the first quarter 2023, 2 other companies have achieved lower Tangible Leverage Ratio than Essa Pharma Inc in the I Quarter 2023. While Tangible Leverage Ratio total ranking has improved so far in the first quarter 2023 to 6, from total ranking in the forth quarter 2023 at 25 .

Explain Tangible Leverage Ratio?
What is EPIX Market Share?
What are EPIX´s Total Liabilities?


EPIX Tangible Leverage Ratio (Dec 31 2023)
I. Quarter
(Sep 30 2023)
IV. Quarter
(Jun 30 2023)
III. Quarter
(Mar 31 2023)
II. Quarter
(Dec 31 2022)
I. Quarter
Y / Y Tangible Equity Change -13.17 % -12.86 % -12.4 % -12.52 % -13.61 %
Y / Y Total Liabilities Change 27.58 % 43.07 % -20.47 % -44.37 % -21.77 %
Tangible Leverage Ratio MRQ 0.03 0.02 0.02 0.01 0.02
EPIX's Total Ranking # 6 # 25 # 28 # 15 # 24
Seq. Tangible Equity Change -3.4 % -3.07 % -3.9 % -3.51 % -3.05 %
Seq. Total Liabilities Change 11.47 % 3.59 % 52.16 % -27.39 % 25 %



Tangible Leverage Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 3
Overall Market # 6


Tangible Leverage Ratio Statistics
High Average Low
0.75 0.18 0.01
(Sep 30 2018)   (Mar 31 2023)




Financial Statements
Essa Pharma Inc 's Tangible Equity $ 141 Millions Visit EPIX's Balance sheet
Essa Pharma Inc 's Total Liabilities $ 4 Millions Visit EPIX's Balance sheet
Source of EPIX's Sales Visit EPIX's Sales by Geography


Cumulative Essa Pharma Inc 's Tangible Leverage Ratio

EPIX's Tangible Leverage Ratio for the trailling 12 Months

EPIX Tangible Leverage Ratio

(Dec 31 2023)
I. Quarter
(Sep 30 2023)
IV. Quarter
(Jun 30 2023)
III. Quarter
(Mar 31 2023)
II. Quarter
(Dec 31 2022)
I. Quarter
Y / Y Tangible Equity TTM Growth -13.17 % -12.86 % -12.4 % -12.52 % -13.61 %
Y / Y Total Liabilities TTM Growth 27.58 % 43.07 % -20.47 % -44.37 % -21.77 %
Tangible Leverage Ratio TTM 0.02 0.02 0.02 0.02 0.02
Total Ranking TTM # 1 # 2 # 12 # 2 # 2
Seq. Tangible Equity TTM Growth -3.4 % -3.07 % -3.9 % -3.51 % -3.05 %
Seq. Total Liabilities TTM Growth 11.47 % 3.59 % 52.16 % -27.39 % 25 %


On the trailing twelve months basis Despite of the net new borrowings of 11.47% during the twelve months period ending in I Quarter 2023 Essa Pharma Inc has managed to unchanged Tangible Leverage Ratio in the I Quarter 2023 to 0.02, below Essa Pharma Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 2, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Essa Pharma Inc . While Tangible Leverage Ratio total ranking has improved so far to 1, from total ranking in previous 12 month period at 2.

Explain Tangible Leverage Ratio?
What is EPIX Market Share?
What are EPIX´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 3
Within the Market # 1


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.75 0.18 0.01
(Sep 30 2018)   (Mar 31 2023)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Tangible Equity
Edgewise Therapeutics inc   0.07 $ 21.205  Millions$ 318.830  Millions
Structure Therapeutics Inc   0.06 $ 29.051  Millions$ 452.966  Millions
Protagonist Therapeutics inc   0.06 $ 21.274  Millions$ 336.677  Millions
Vistagen Therapeutics Inc   0.06 $ 7.783  Millions$ 123.285  Millions
Sagimet Biosciences inc   0.06 $ 5.589  Millions$ 91.065  Millions
Moonlake Immunotherapeutics  0.06 $ 28.364  Millions$ 513.491  Millions
Diamedica Therapeutics Inc   0.05 $ 2.703  Millions$ 51.057  Millions
Belite Bio Inc  0.05 $ 4.211  Millions$ 90.431  Millions
Astria Therapeutics inc   0.05 $ 11.221  Millions$ 243.116  Millions
Mineralys Therapeutics Inc   0.04 $ 10.482  Millions$ 241.154  Millions
Morphic Holding inc   0.04 $ 25.492  Millions$ 697.022  Millions
Xbiotech Inc   0.04 $ 7.769  Millions$ 218.846  Millions
Gh Research Plc  0.03 $ 7.332  Millions$ 218.968  Millions
Altimmune Inc   0.03 $ 6.468  Millions$ 194.099  Millions
Anixa Biosciences Inc   0.03 $ 0.767  Millions$ 23.604  Millions
Essa Pharma inc   0.03 $ 3.806  Millions$ 140.683  Millions

Date modified: 2024-02-13T17:23:09+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com